The launch of Invista, a formulation of Dasatinib was announced by Dr. Reddy’s Laboratories. It is a equivalent to the innovator brand. It is to be used for the treatment of chronic accelerated or myeloid or lymphoid blast phase and newly diagnosed in chronic phase adult patients with Chronic Myeloid Leukemia (CML) in India.
Commenting on the launch, M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr Reddy’s Laboratories said, “We are pleased to bring this important and complex product to the market in India. The development and launch of Invista is a significant step forward in improving access to medicines at an affordable price for CML patients in India.
It is available in strengths of 50, 70 and 100 mg tablets.